On Monday, the FDA gave approval to NovoNordisk’s new combination product, Xultophy. This is a combination of the super long-acting insulin degludec and the once daily GLP-1 agonist Liraglutide. The fixed dose combination is given in one to 50 dosing steps to maximize to glycemic control. The super long-acting insulin …

In my experience, most people will check their fasting glucose levels, but due to time, place, not enough strips, or just the fact they don’t want to see…many will not check after eating. For those who will only check once a day, I recommend alternating a fasting blood glucose check with a bedtime blood glucose check.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 4 of this Exclusive Interview, Dr. Mechanick explains the improved understanding of the need for the expertise of an endocrinologist in helping the prediabetes patient.

In this week's Homerun Slides, the ideal glucose sensor for clinical care.

The incretin effect in health: The idea that gastrointestinal factors contribute to the control of postprandial glucose regulation dates back to the beginning of the twentieth century, when Moore and colleagues reported reductions in glucosuria after the oral administration of gut extracts xin patients with juvenile diabetes. Even though it is questionable whether these glucose-lowering effects were really attributable to the incretin activity of the extract (which is unlikely, because most gastrointestinal peptide hormones are inactivated by the gastric acid), this report can be considered as the first description of an incretin-like effect.